guselkumab vs SOR102

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

QUASAR/GALAXI · Phase 3 · completed

Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT06260163 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)

Result source: NCT05528510

SOR102

Developed by Sorriso Pharmaceuticals

Phase 1 in Ulcerative ColitisBiologic (oral dual TNFα/IL-23(p19) inhibitor)
Weak signal

NCT06080048 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Treatment Emergent Adverse Events following oral dosing". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Treatment Emergent Adverse Events following oral dosing (Up to 6 weeks in Part 3 or at the time of study discontinuation): First-in-human phase 1. Part 1 (healthy participants): treatment-emergent adverse events in 3/24 (13%) receiving SOR102 versus 2/8 (25%) receiving placebo. Part 2: no treatment-emergent adverse events in the 10 participants receiving twice-daily SOR102. Part 3 (ulcerative colitis patients): at least one adverse event in 7/16 (44%) treated with SOR102 and 3/6 (50%) receiving placebo. Rates of clinical response ranged from 29% to 67%, depending on the definition applied.

Result source: NCT06080048

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabSOR102
Clinical remission (induction)22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
—Not reported
Clinical remission (maintenance)50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
—Not reported
Clinical response (induction)61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
—Not reported
Endoscopic improvement (induction)—Trial running · NCT04033445—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT04033445—Not reported

Clinical remission (induction)

guselkumab
22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
SOR102
—Not reported

Clinical remission (maintenance)

guselkumab
50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
SOR102
—Not reported

Clinical response (induction)

guselkumab
61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
SOR102
—Not reported

Endoscopic improvement (induction)

guselkumab
—Trial running · NCT04033445
SOR102
—Not reported

Corticosteroid-free remission (maintenance)

guselkumab
—Trial running · NCT04033445
SOR102
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SOR102: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. guselkumab: 4 of 4 rows · SOR102: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Dropout rate
2.8%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.1%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0.9%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.6%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3.8%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6.5%200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
5.6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.3%100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.5%100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.7%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.4%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
2.8%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.2%Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
0%Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
3.1%Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
200 mg IVa
anaemia 7.4% (placebo 10.2%)
covid-19 5.6% (placebo 4.6%)
abdominal pain 3.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
200 mg IV
anaemia 6% (placebo 10.2%)
upper respiratory tract infection 4.5% (placebo 0%)
colitis ulcerative 3% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
colitis ulcerative 3.8% (placebo 2.8%)
headache 3.8% (placebo 7.4%)
anaemia 2.5% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
anaemia 5% (placebo 10.2%)
covid-19 5% (placebo 4.6%)
headache 3% (placebo 7.4%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
covid-19 7.6% (placebo 4.6%)
colitis ulcerative 4.1% (placebo 2.8%)
nasopharyngitis 2.9% (placebo 1.9%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
covid-19 7% (placebo 4.6%)
colitis ulcerative 5.4% (placebo 2.8%)
anaemia 4.7% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w to 200 mg SC q4w
colitis ulcerative 16.1% (placebo 2.8%)
covid-19 6.5% (placebo 4.6%)
abdominal pain 3.2% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
covid-19 18.4% (placebo 4.6%)
colitis ulcerative 16.8% (placebo 2.8%)
pyrexia 6.4% (placebo 4.6%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
colitis ulcerative 13.1% (placebo 2.8%)
covid-19 10.1% (placebo 4.6%)
arthralgia 8% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w to 200 mg SC q4w
covid-19 13% (placebo 4.6%)
anaemia 8.7% (placebo 10.2%)
colitis ulcerative 8.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w
covid-19 14.2% (placebo 4.6%)
colitis ulcerative 10.2% (placebo 2.8%)
arthralgia 6.1% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
400 mg IV
anaemia 8.1% (placebo 10.2%)
headache 5.4% (placebo 7.4%)
arthralgia 3.6% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
anaemia 5.6%
colitis ulcerative 5.6%
headache 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.5%
upper respiratory tract infection 7%
neutropenia 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
colitis ulcerative 8.5%
upper respiratory tract infection 8.5%
headache 4.2%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.6%
headache 7.1%
colitis ulcerative 5.7%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
anaemia 0%
colitis ulcerative 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 1.5%
colitis ulcerative 1.5%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

Clinical Response 61.4% (n=101) vs 27.6% (n=105) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more results
60.7% (n=107) vs 27.6% (n=105) placebo @ 12wk400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
74.6% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
83.1% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
Clinical Remission 22.6% (n=421) vs 7.9% (n=280) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 4 more results
50% (n=190) vs 18.9% (n=190) placebo @ 44wk200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
45.2% (n=188) vs 18.9% (n=190) placebo @ 44wk100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
21.1% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
36.6% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · SOR102's landscape